Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis

References

• Gupta A, Kumar L, Dabkara D, et al. Multiple myeloma: autologous stem cell transplantation versus conventional chemotherapy—a retrospective age and stage matched analysis. J Clin Oncol. 2009;27:7041.
   Web of Science ®Google Scholar
• Cunningham D, Paz-Ares L, Gore ME, et al. High-dose melphalan for multiple myeloma: long-term follow-up data. J Clin Oncol. 1994;12(4):764–768.
   PubMed Web of Science ®Google Scholar
• Lahuerta JJ, Grande C, Blade J, et al. Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish Registry for transplantation in multiple myeloma. Leuk Lymphoma. 2002;43(1):67–75.
   PubMed Web of Science ®Google Scholar
• Jung S-H, Lee J-J, Kim JS, et al. Phase 2 study of an intravenous busulfan and melphalan conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma (KMM150). Biol Blood Marrow Transplant. 2018;24(5):923–929.
   PubMed Web of Science ®Google Scholar
• Greipp PR, Miguel JS, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420.
   PubMed Web of Science ®Google Scholar
• Durie BGM, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467–1473.
   PubMed Web of Science ®Google Scholar
• Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44(6):778–783.
   PubMed Web of Science ®Google Scholar
• McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118(4):255–267.
   PubMed Web of Science ®Google Scholar
• Bashir Q, Thall PF, Milton DR, et al. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol. 2019;6(5):e266–e275.
   PubMed Web of Science ®Google Scholar
• Ria R, Falzetti F, Ballanti S, et al. Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma. Hematol J. 2004;5(2):118–122.
   PubMedGoogle Scholar
• Lahuerta JJ, Mateos MV, Martínez-López J, et al. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Haematologica. 2010;95(11):1913–1920.
   PubMed Web of Science ®Google Scholar
• Blanes M, Lahuerta JJ, González JD, et al. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach. Biol Blood Marrow Transplant. 2013;19(1):69–74.
   PubMed Web of Science ®Google Scholar
• Schuler US, Ehrsam M, Schneider A, et al. Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation. Bone Marrow Transplant. 1998;22(3):241–244.
   PubMed Web of Science ®Google Scholar
• Davis JM, Ivanova A, Chung Y, et al. Evaluation of a test dose strategy for pharmacokinetically-guided busulfan dosing for hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25(2):391–397.
   PubMed Web of Science ®Google Scholar
• Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997;89(8):3055–3060.
   PubMed Web of Science ®Google Scholar
• Salman B, Al-Za’abi M, Al-Huneini M, et al. Therapeutic drug monitoring-guided dosing of busulfan differs from weight-based dosing in hematopoietic stem cell transplant patients. Hematol Oncol Stem Cell Ther. 2017;10(2):70–78.
   PubMedGoogle Scholar
• Blanes M, Lorenzo JI, Ribas P, et al. Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma. Ann Hematol. 2019;98(8):2013–2015.
   PubMed Web of Science ®Google Scholar
• Korde N, Roschewski M, Zingone A, et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol. 2015;1(6):746–754.
   PubMed Web of Science ®Google Scholar
• Paiva B, Vidriales M-B, Cerveró J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112(10):4017–4023.
   PubMed Web of Science ®Google Scholar
• Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123(20):3073–3079.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Gregory WM, de Tute RM, et al. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood. 2015;125(12):1932–1935.
   PubMed Web of Science ®Google Scholar
• Lahuerta J-J, Paiva B, Vidriales M-B, et al. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials. JCO. 2017;35(25):2900–2910.
   PubMed Web of Science ®Google Scholar
• Gonsalves WI, Gertz MA, Dispenzieri A, et al. Implications of continued response after autologous stem cell transplantation for multiple myeloma. Blood. 2013;122(10):1746–1749.
   PubMed Web of Science ®Google Scholar